L'intérêt à découvert pour Krystal Biotech donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Krystal Biotech. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Krystal Biotech (NASDAQ:KRYS) Stock, Rapport sur les intérêts à découvert

Krystal Biotech

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Krystal Biotech Inc

Needham analyst Bernie McTernan reiterates Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Buy and maintains $56 price target.

News

Price Target

Reiteration

Analyst Ratings

CART

Needham Reiterates Buy on Maplebear, Maintains $56 Price Target

Needham analyst Charles Shi reiterates Cohu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COHU#NASDAQ">COHU</a>) from Hold to Hold.

COHU

Needham Reiterates Hold on Cohuto Hold

Telsey Advisory Group analyst Dana Telsey maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Market Perform and lowers the price target from $10 to $9.

Telsey Advisory Group Maintains Market Perform on Kohl's, Lowers Price Target to $9

Needham analyst Ryan MacDonald reiterates American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) from Hold to Hold.

AMWL

Needham Reiterates Hold on American Wellto Hold

Telsey Advisory Group analyst Joseph Feldman maintains Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) with a Market Perform and lowers the price target from $2.5 to $2.

COOK

Telsey Advisory Group Maintains Market Perform on Traeger, Lowers Price Target to $2

Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) affirms FY2025 GAAP EPS guidance from $4.70-$5.10 to $4.70-$5.10 vs $4.17 analyst estimate. Affirms FY2025 sales outlook from $5.30 billion-$5.50 billion to $5.30 billion-$5.50 billion vs $5.29 billion estimate.

Guidance

Terex Affirms FY2025 GAAP EPS Guidance of $4.70-$5.10 vs $4.17 Est; Affirms FY2025 Sales Guidance of $5.30B-$5.50B vs $5.29B Est

Westlake Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.38 by 63.16 percent. This is a 66.67 percent decrease over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $237.63 million which missed the analyst consensus estimate of $296.00 million by 19.72 percent. This is a 16.53 percent decrease over sales of $284.67 million the same period last year.

Earnings

Earnings Misses

WLKP

Westlake Chemical Q1 EPS $0.14 Misses $0.38 Estimate, Sales $237.63M Miss $296.00M Estimate

Keybanc analyst Brandon Nispel downgrades Cable One (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABO#NYSE">CABO</a>) from Overweight to Sector Weight.

Downgrades

CABO

Keybanc Downgrades Cable One to Sector Weight

nVent Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) reported quarterly earnings of $0.67 per share which met the analyst consensus estimate. This is a 12.99 percent decrease over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $809.30 million which beat the analyst consensus estimate of $791.24 million by 2.28 percent. This is a 7.47 percent decrease over sales of $874.60 million the same period last year.

Earnings Beats

nVent Electric Q1 Adj. EPS $0.67, Inline, Sales $809.30M Beat $791.24M Estimate

Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.49 by 69.39 percent. This is a 48.13 percent decrease over earnings of $1.60 per share from the same period last year. The company reported quarterly sales of $1.23 billion which missed the analyst consensus estimate of $1.24 billion by 0.86 percent. This is a 4.95 percent decrease over sales of $1.29 billion the same period last year.

Terex Q1 Adj. EPS $0.83 Beats $0.49 Estimate, Sales $1.23B Miss $1.24B Estimate

Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) lowers FY2025 GAAP EPS guidance from $10.60-$11.00 to $10.29-$10.69 vs $11.24 analyst estimate..

Eaton Corp Lowers FY2025 GAAP EPS Guidance from $10.60-$11.00 to $10.29-$10.69 vs $11.24 Est

BFLY

Butterfly Network Reiterates FY25 Revenue Outlook Of $96M - $100M Vs. $97.745M Est.

Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) is looking for Q2 GAAP EPS of $2.35-$2.45 vs $2.80 analyst estimate..

Eaton Corp Sees Q2 GAAP EPS $2.35-$2.45 vs $2.80 Est

Xenia Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHR#NYSE">XHR</a>) widens FY2025 FFO guidance from $1.55-$1.74 to $1.50-$1.75 vs $1.57 analyst estimate..

Xenia Hotels & Resorts Widens FY2025 FFO Guidance from $1.55-$1.74 to $1.50-$1.75 vs $1.57 Est

Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) is looking for Q2 Adj EPS of $2.85-$2.95 vs $2.98 analyst estimate..

Eaton Corp Sees Q2 Adj EPS $2.85-$2.95 vs $2.98 Est

Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) affirms FY2025 Adj EPS guidance from $11.80-$12.20 to $11.80-$12.20 vs $11.97 analyst estimate..

Eaton Corp Affirms FY2025 Adj EPS Guidance of $11.80-$12.20 vs $11.97 Est

Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $0.68 by 145.59 percent. This is a 123.13 percent decrease over earnings of $1.34 per share from the same period last year. The company reported quarterly sales of $2.85 billion which missed the analyst consensus estimate of $2.95 billion by 3.52 percent. This is a 4.34 percent decrease over sales of $2.98 billion the same period last year.

Westlake Q1 EPS $(0.31) Misses $0.68 Estimate, Sales $2.85B Miss $2.95B Estimate

Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) reported quarterly earnings of $1.82 per share which missed the analyst consensus estimate of $1.96 by 7.14 percent. This is a 5.81 percent increase over earnings of $1.72 per share from the same period last year. The company reported quarterly sales of $5.55 billion which beat the analyst consensus estimate of $4.64 billion by 19.44 percent. This is a 21.19 percent decrease over sales of $7.04 billion the same period last year.

Apollo Global Management Q1 Adj. EPS $1.82 Misses $1.96 Estimate, Sales $5.55B Beat $4.64B Estimate

Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) reported quarterly earnings of $2.72 per share which beat the analyst consensus estimate of $2.71 by 0.37 percent. This is a 13.33 percent increase over earnings of $2.40 per share from the same period last year. The company reported quarterly sales of $6.38 billion which beat the analyst consensus estimate of $6.26 billion by 1.93 percent. This is a 7.30 percent increase over sales of $5.94 billion the same period last year.

Eaton Corp Q1 Adj. EPS $2.72 Beats $2.71 Estimate, Sales $6.38B Beat $6.26B Estimate

Xenia Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHR#NYSE">XHR</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.42 by 21.43 percent. This is a 15.91 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $288.93 million which beat the analyst consensus estimate of $275.38 million by 4.92 percent. This is a 8.01 percent increase over sales of $267.49 million the same period last year.

Comments

Krystal Biotech

Intérêt court

Krystal Biotech (NASDAQ:KRYS) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL